Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Lyell Immunopharma, Inc.

NASDAQ: LYEL · Life Sciences · 5 alerts · CIK 1806952

Share price
$14.65Close, Nov 16
Market cap
$360M
Shares outstanding
24.59MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Lyell Immunopharma, Inc. filings on SEC EDGAR ↗

5:36 PM ET Form 4
Insider Buying

Lyell Immunopharma Insider ARCH Venture Partners IX LLC Buys $25M of Stock

ARCH Venture Partners IX LLC bought 2,321,262 shares of Lyell Immunopharma, Inc. at $10.77 a share, worth $25M in total on Nov 4, 2026. Shares held after the trade: 3,747,790 (+162.7%).

Value
$25M
Shares
2,321,262
Price
$10.77
Holding change
+162.7%
Trade date
Nov 4, 2026
5:34 PM ET Form 4
Insider Buying

Lyell Immunopharma Insider ARCH Venture Fund XIII L.P. Buys $25M of Stock

ARCH Venture Fund XIII L.P. bought 2,321,262 shares of Lyell Immunopharma, Inc. at $10.77 a share, worth $25M in total on Nov 4, 2026. Shares held after the trade: 3,747,790 (+162.7%).

Value
$25M
Shares
2,321,262
Price
$10.77
Holding change
+162.7%
Trade date
Nov 4, 2026
4:18 PM ET 10-Q
Financial Results

Lyell Immunopharma Q3 2026 Results: Net Loss of $45.5M, Loss Widens

Lyell Immunopharma reported total assets of $273.9 million as of September 30, 2026, a decrease from $340.1 million at the end of 2025. The company's liquidity is primarily held in cash, cash equivalents, and marketable securities totaling approximately $194 million, which it intends to use to fund the development of its lead product candidates, ronde-cel and LYL273.

Key figure
Net loss $45.5M
4:15 PM ET 8-K
Financial Results

Lyell Immunopharma Financial Results

Lyell Immunopharma reported Q3 2026 financial results and provided clinical updates for its CAR T-cell therapy ronde-cel, which showed a 91% overall response rate in the PiNACLE trial. The company also announced an $80 million private placement financing, extending its cash runway into 2028.

“The updated ronde-cel data accepted for presentation at ASH further strengthen our conviction in ronde-cel’s potential to meaningfully improve outcomes for patients with large B-cell lymphoma. The high rates of very durable complete responses achieved by ronde-cel in both the second- and third- or later-line settings, including in patients with high-risk primary refractory disease, clearly showcase the next-generation potential of ronde-cel.”

Lynn Seely, M.D., President and Chief Executive Officer of Lyell
9:07 AM ET 8-K
Capital Raise

Lyell Immunopharma Capital Raise of $80M

Lyell Immunopharma entered into a securities purchase agreement to raise $80.0 million through a private placement of 7,428,040 shares of common stock. The shares were sold to institutional accredited investors at a price of $10.77 per share, with the company agreeing to file a resale registration statement within 30 days of closing.

Value
$80M
Counterparty
institutional accredited investors

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.